Skip to main content

Table 3 Rheumatoid factor (RF) ELISA analysis of ADA-positive IFX-treated patients and ADA-negative untreated healthy control sera

From: B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera

Patient ID RF (U/ml) Control ID RF (U/ml)
IgM IgA IgG IgM IgA IgG
438 1.1 1.4 30.7 P* 2.0 3.4 8.4
452 5.1 2.8 5.0 F10 3.5 6.5 15.0
485 1.4 1.8 6.2 F22 1.9 2.3 14.2
522 1.7 3.2 16.4 F28 nd nd nd
587 3.3 2.0 3.6 F31 2.3 1.8 7.2
609 3.8 9.1 18.3 F32 3.1 18.9 5.7
623 3.1 8.1 10.2 F33 3.9 3.4 7.4
626 2.9 8.2 9.4 F34 1.3 2.4 8.4
638 2.7 2.8 4.7 F38 2.8 5.2 10.3
639 2.7 2.3 5.0 F41 2.2 2.0 10.3
648 2.3 11.4 27.5 F42 1.5 3.2 13.1
652 1.9 7.8 12.3 F44 3.5 28.3 11.3
660 2.2 3.4 12.3 F45 0.9 0.2 3.4
681 1.3 12.2 8.7 F46 2.2 3.5 24.4
694 2.9 3.3 10.2 F47 nd nd nd
695 2.9 4.0 14.5     
719 1.1 8.8 7.4     
721 2.7 0.9 4.1     
722 4.4 4.5 3.3     
724 0.9 21 4.8     
  1. RF ELISA results are considered being negative when below 10 U/ml for IgM, 25 U/ml for IgA, and 20 U/ml for IgG antibodies
  2. nd not determined